FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair – FiercePharma


Fox News

FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair
FiercePharma
It was way back in 2009 when the FDA first indicated it was worried about reports of heart attacks and strokes in patients taking Xolair, the asthma treatment co-marketed by Novartis ($NVS) and Roche ($RHHBY). Now the agency is taking action, slapping …
FDA says asthma drug Xolair raises risk of heart, brain problemsFox News
Heart, Mini-Stroke Risks From Asthma Drug: FDAWebMD
FDA adds cardiovascular risks to Xolair label for asthma treatmentHealio
ModernMedicine
all 6 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.